Q3 Revenue Falls 9.6% as Biote's Turnaround Stalls; Guidance Held
BTMD sits 23% above its 52-week low of $1.
Summary
Revenue dropped 9.6% to $43.3 million and procedure revenue fell 15.1% to $28.9 million, with interim CEO Bob Peterson conceding the return to growth is 'progressing more slowly than anticipated.' Adjusted EBITDA collapsed to $5.1 million from $12.9 million a year ago, and gross margin slipped to 67.7% from 71.8% on continued use of lower-margin third-party pellets after the January 2026 recall. Net income was just $0.6 million, or $0.01 per diluted share, versus $9.2 million and $0.22 a year earlier. Cash fell to $8.9 million from $24.1 million at year-end, a thin cushion against a $117 million term loan. Management kept full-year 2026 guidance unchanged at revenue above $175 million and adjusted EBITDA above $25 million, which now looks stretched given the nine-month revenue run rate of $132.5 million.
At the time of this announcement, BTMD was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.2M. The 52-week trading range was $1.00 to $2.98. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.